Prashant Reddy

The New Drugs Bill: A missed opportunity for reforms in Ayush

The Bill takes regressive steps on the issue of drug safety

GVK BIO to acquire US-based Aragen Bioscience

Financial details undisclosed; this is GVK BIO's first international acquisition

Dr Reddy's ties up with Galena Biopharma for commercialisation of cancer vaccine

NeuVax is a vaccine aimed at preventing the recurrence of breast cancer in patients under remission

The problem with punitive damages

Interim justice: Troubling trend

Indian courts must protect intellectual property rights, but they must decide patent infringement cases only after a trial where both parties are allowed to produce evidence to assert their claims

Prashant Reddy: The regulatory mess in Indian science

From nuclear power plants to GM foods to chemical trials of new drugs, almost every issue has ended up in the Supreme Court, which is far from ready to handle the regulation of science

Prashant Reddy T: Tribunals stuffed with bureaucrats

SAT member P K Malhotra¿s appointment as law secretary flies in the face of propriety and legality

Prashant Reddy: RTI law is for lawyers

Did the Supreme Court's recent order on the RTI go too far - or not far enough?

Prashant Reddy: The publishing wars

Destroying the incentive to publish by bringing in wide exceptions to copyright law is only going to ensure few incentives for the publishing industry